Cargando…
Single center analysis of an advisable control interval for follow-up of patients with PI-RADS category 3 in multiparametric MRI of the prostate
To evaluate if follow-up mpMRI scans of patients in PI-RADS category 3 are safe enough to omit or delay prostate biopsy in the future and to determine an optimal control interval. This retrospective single center study includes consecutive PI-RADS category 3 patients with one or more follow-up mpMRI...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9038748/ https://www.ncbi.nlm.nih.gov/pubmed/35469056 http://dx.doi.org/10.1038/s41598-022-10859-9 |
_version_ | 1784693971117670400 |
---|---|
author | Boschheidgen, M. Schimmöller, L. Doerfler, S. Al-Monajjed, R. Morawitz, J. Ziayee, F. Mally, D. Quentin, M. Arsov, C. Albers, P. Antoch, G. Ullrich, T. |
author_facet | Boschheidgen, M. Schimmöller, L. Doerfler, S. Al-Monajjed, R. Morawitz, J. Ziayee, F. Mally, D. Quentin, M. Arsov, C. Albers, P. Antoch, G. Ullrich, T. |
author_sort | Boschheidgen, M. |
collection | PubMed |
description | To evaluate if follow-up mpMRI scans of patients in PI-RADS category 3 are safe enough to omit or delay prostate biopsy in the future and to determine an optimal control interval. This retrospective single center study includes consecutive PI-RADS category 3 patients with one or more follow-up mpMRI (T2WI, DWI, DCE) and subsequent MRI-targeted and systematic TRUS-guided biopsy between 2012 and 2018. Primary study objective was the verification of a significant PI-RADS category upgrade in follow-up mpMRI in patients with subsequent PCA positive biopsy versus patients with negative biopsy. Further objectives were development of the PI-RADS category and clinical parameters between initial and follow-up mpMRI in the context of histopathologic results and time interval. Eighty-nine patients (median PSA 6.6 ng/ml; PSAD 0.13 ng/ml/ml) were finally included (follow-up period 31 ± 18 months). 19 cases had PCA (median PSA 7.8 ng/ml; PSAD 0.14 ng/ml/ml). 4 cases had csPCA (median PSA 5.4 ng/ml; PSAD 0.13 ng/ml/ml) for which there was a significant PI-RADS upgrade after 12–24 months (mean 3.75; p = 0.01) compared to patients without PCA (mean 2.74). Without PCA the mean PI-RADS category decreased after 25–36 months (mean 2.74; p = 0.02). Clinical parameters did not change significantly except a PSAD increase for PCA patients after 24 months. Patients within PI-RADS category 3 may not need prompt biopsy since those with PCA reliably demonstrate a PI-RADS category upgrade in follow-up mpMRI after 12–24 months. PI-RADS 3 patients with negative biopsy do not benefit from follow-up mpMRI earlier than 24 months. |
format | Online Article Text |
id | pubmed-9038748 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-90387482022-04-27 Single center analysis of an advisable control interval for follow-up of patients with PI-RADS category 3 in multiparametric MRI of the prostate Boschheidgen, M. Schimmöller, L. Doerfler, S. Al-Monajjed, R. Morawitz, J. Ziayee, F. Mally, D. Quentin, M. Arsov, C. Albers, P. Antoch, G. Ullrich, T. Sci Rep Article To evaluate if follow-up mpMRI scans of patients in PI-RADS category 3 are safe enough to omit or delay prostate biopsy in the future and to determine an optimal control interval. This retrospective single center study includes consecutive PI-RADS category 3 patients with one or more follow-up mpMRI (T2WI, DWI, DCE) and subsequent MRI-targeted and systematic TRUS-guided biopsy between 2012 and 2018. Primary study objective was the verification of a significant PI-RADS category upgrade in follow-up mpMRI in patients with subsequent PCA positive biopsy versus patients with negative biopsy. Further objectives were development of the PI-RADS category and clinical parameters between initial and follow-up mpMRI in the context of histopathologic results and time interval. Eighty-nine patients (median PSA 6.6 ng/ml; PSAD 0.13 ng/ml/ml) were finally included (follow-up period 31 ± 18 months). 19 cases had PCA (median PSA 7.8 ng/ml; PSAD 0.14 ng/ml/ml). 4 cases had csPCA (median PSA 5.4 ng/ml; PSAD 0.13 ng/ml/ml) for which there was a significant PI-RADS upgrade after 12–24 months (mean 3.75; p = 0.01) compared to patients without PCA (mean 2.74). Without PCA the mean PI-RADS category decreased after 25–36 months (mean 2.74; p = 0.02). Clinical parameters did not change significantly except a PSAD increase for PCA patients after 24 months. Patients within PI-RADS category 3 may not need prompt biopsy since those with PCA reliably demonstrate a PI-RADS category upgrade in follow-up mpMRI after 12–24 months. PI-RADS 3 patients with negative biopsy do not benefit from follow-up mpMRI earlier than 24 months. Nature Publishing Group UK 2022-04-25 /pmc/articles/PMC9038748/ /pubmed/35469056 http://dx.doi.org/10.1038/s41598-022-10859-9 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Boschheidgen, M. Schimmöller, L. Doerfler, S. Al-Monajjed, R. Morawitz, J. Ziayee, F. Mally, D. Quentin, M. Arsov, C. Albers, P. Antoch, G. Ullrich, T. Single center analysis of an advisable control interval for follow-up of patients with PI-RADS category 3 in multiparametric MRI of the prostate |
title | Single center analysis of an advisable control interval for follow-up of patients with PI-RADS category 3 in multiparametric MRI of the prostate |
title_full | Single center analysis of an advisable control interval for follow-up of patients with PI-RADS category 3 in multiparametric MRI of the prostate |
title_fullStr | Single center analysis of an advisable control interval for follow-up of patients with PI-RADS category 3 in multiparametric MRI of the prostate |
title_full_unstemmed | Single center analysis of an advisable control interval for follow-up of patients with PI-RADS category 3 in multiparametric MRI of the prostate |
title_short | Single center analysis of an advisable control interval for follow-up of patients with PI-RADS category 3 in multiparametric MRI of the prostate |
title_sort | single center analysis of an advisable control interval for follow-up of patients with pi-rads category 3 in multiparametric mri of the prostate |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9038748/ https://www.ncbi.nlm.nih.gov/pubmed/35469056 http://dx.doi.org/10.1038/s41598-022-10859-9 |
work_keys_str_mv | AT boschheidgenm singlecenteranalysisofanadvisablecontrolintervalforfollowupofpatientswithpiradscategory3inmultiparametricmrioftheprostate AT schimmollerl singlecenteranalysisofanadvisablecontrolintervalforfollowupofpatientswithpiradscategory3inmultiparametricmrioftheprostate AT doerflers singlecenteranalysisofanadvisablecontrolintervalforfollowupofpatientswithpiradscategory3inmultiparametricmrioftheprostate AT almonajjedr singlecenteranalysisofanadvisablecontrolintervalforfollowupofpatientswithpiradscategory3inmultiparametricmrioftheprostate AT morawitzj singlecenteranalysisofanadvisablecontrolintervalforfollowupofpatientswithpiradscategory3inmultiparametricmrioftheprostate AT ziayeef singlecenteranalysisofanadvisablecontrolintervalforfollowupofpatientswithpiradscategory3inmultiparametricmrioftheprostate AT mallyd singlecenteranalysisofanadvisablecontrolintervalforfollowupofpatientswithpiradscategory3inmultiparametricmrioftheprostate AT quentinm singlecenteranalysisofanadvisablecontrolintervalforfollowupofpatientswithpiradscategory3inmultiparametricmrioftheprostate AT arsovc singlecenteranalysisofanadvisablecontrolintervalforfollowupofpatientswithpiradscategory3inmultiparametricmrioftheprostate AT albersp singlecenteranalysisofanadvisablecontrolintervalforfollowupofpatientswithpiradscategory3inmultiparametricmrioftheprostate AT antochg singlecenteranalysisofanadvisablecontrolintervalforfollowupofpatientswithpiradscategory3inmultiparametricmrioftheprostate AT ullricht singlecenteranalysisofanadvisablecontrolintervalforfollowupofpatientswithpiradscategory3inmultiparametricmrioftheprostate |